MD20160111A2 - Derivaţi diheterociclici legaţi de cicloalchil - Google Patents

Derivaţi diheterociclici legaţi de cicloalchil

Info

Publication number
MD20160111A2
MD20160111A2 MDA20160111A MD20160111A MD20160111A2 MD 20160111 A2 MD20160111 A2 MD 20160111A2 MD A20160111 A MDA20160111 A MD A20160111A MD 20160111 A MD20160111 A MD 20160111A MD 20160111 A2 MD20160111 A2 MD 20160111A2
Authority
MD
Moldova
Prior art keywords
cycloalkyl
compounds
derivatives
linked
mammals
Prior art date
Application number
MDA20160111A
Other languages
English (en)
Russian (ru)
Inventor
Аарон Крейг БЕРНС
Майкл Рэймонд Коллинс
Саманта Элизабет Грисли
Роберт Луис Хоффман
Циньхуа Хуан
Роберт Стивен Кания
Пэй-Пэй Кун
Мария Анджелика Линтон
Лакшми Сурираджан НАРАСИМХА
Пол Фрэнсис Ричардсон
Дэниел Тайлер РИХТЕР
Грэм СМИТ
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of MD20160111A2 publication Critical patent/MD20160111A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Invenţia se referă la compuşi cu formula (I)(I)sau la săruri farmaceutic acceptabile ale acestora, unde A, L, D, R1-R6, x şi y sunt definiţi în descrierea invenţiei. Derivaţii diheterociclici noi legaţi de cicloalchil sunt utilizaţi în tratamentul creşterii anormale a celulelor, astfel ca cancerul, la mamifere. Prezenta invenţie de asemenea se referă la compoziţii farmaceutice, care conţin compuşi, şi la metode de utilizare a compuşilor şi compoziţiilor în tratamentul creşterii anormale a celulelor la mamifere.
MDA20160111A 2014-04-30 2015-04-17 Derivaţi diheterociclici legaţi de cicloalchil MD20160111A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986876P 2014-04-30 2014-04-30
PCT/IB2015/052833 WO2015166373A1 (en) 2014-04-30 2015-04-17 Cycloalkyl-linked diheterocycle derivatives

Publications (1)

Publication Number Publication Date
MD20160111A2 true MD20160111A2 (ro) 2017-06-30

Family

ID=53276932

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160111A MD20160111A2 (ro) 2014-04-30 2015-04-17 Derivaţi diheterociclici legaţi de cicloalchil

Country Status (41)

Country Link
US (4) US20170050958A1 (ro)
EP (2) EP3556757A1 (ro)
JP (2) JP6574203B2 (ro)
KR (1) KR20160149256A (ro)
CN (1) CN106232598B (ro)
AP (1) AP2016009530A0 (ro)
AU (1) AU2015254943B2 (ro)
BR (1) BR112016024513A2 (ro)
CA (1) CA2947130C (ro)
CL (1) CL2016002532A1 (ro)
CR (1) CR20160497A (ro)
CU (1) CU24420B1 (ro)
CY (1) CY1122439T1 (ro)
DK (1) DK3137460T3 (ro)
DO (1) DOP2016000293A (ro)
EA (1) EA033919B1 (ro)
EC (1) ECSP16083017A (ro)
ES (1) ES2759434T3 (ro)
GE (1) GEP20186879B (ro)
GT (1) GT201600232A (ro)
HK (1) HK1232212A1 (ro)
HR (1) HRP20192056T1 (ro)
HU (1) HUE046518T2 (ro)
IL (1) IL248629B (ro)
LT (1) LT3137460T (ro)
MA (2) MA39926B1 (ro)
MD (1) MD20160111A2 (ro)
MX (1) MX2016014143A (ro)
NI (1) NI201600163A (ro)
NZ (1) NZ725496A (ro)
PE (1) PE20161436A1 (ro)
PH (1) PH12016501997A1 (ro)
PL (1) PL3137460T3 (ro)
PT (1) PT3137460T (ro)
RS (1) RS59617B1 (ro)
SG (1) SG11201608634RA (ro)
SI (1) SI3137460T1 (ro)
SV (1) SV2016005310A (ro)
TN (1) TN2016000459A1 (ro)
UA (1) UA117861C2 (ro)
WO (1) WO2015166373A1 (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6783663B2 (ja) * 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
PT3137460T (pt) * 2014-04-30 2019-12-30 Pfizer Derivados de di-heterociclo ligado a cicloalquilo
CN107474024B (zh) * 2016-06-08 2022-12-13 北京赛林泰医药技术有限公司 一种谷氨酰酶抑制剂及其组合物和用途
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JPH09104838A (ja) 1995-10-09 1997-04-22 Mitsui Toatsu Chem Inc 水性塗料用樹脂組成物
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
HUP0103617A2 (hu) 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2413424C (en) 2000-06-22 2007-10-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10109807A1 (de) 2001-03-01 2002-09-05 Wella Ag Verbrückte Diaminopyrazole und diese Verbindungen enthaltende Färbemittel
US7029729B2 (en) 2003-02-24 2006-04-18 3M Innovative Properties Company Cholesteric liquid crystal additives
DE602004004278T2 (de) 2003-08-15 2007-10-31 Merck & Co, Inc. 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
WO2006028269A2 (en) 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 ihibitory activity
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
SG11201402305WA (en) * 2011-11-21 2014-06-27 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
US9672526B2 (en) 2012-03-13 2017-06-06 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
WO2014031933A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
MX2015005963A (es) * 2012-11-16 2015-09-16 Calithera Biosciences Inc Inhibidores heterociclicos de glutaminasa.
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
US9029531B2 (en) * 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CN105283182A (zh) 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
WO2015048246A1 (en) * 2013-09-27 2015-04-02 The Board Of Trustees Of The University Of Illinois Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
JP6783663B2 (ja) * 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EA201691896A1 (ru) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. Соединения и способы их применения
PT3137460T (pt) 2014-04-30 2019-12-30 Pfizer Derivados de di-heterociclo ligado a cicloalquilo
JP6798890B2 (ja) 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
WO2016160980A1 (en) 2015-03-30 2016-10-06 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
JP6944377B2 (ja) 2015-04-06 2021-10-06 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼの阻害剤を用いる肺がんの処置
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
US10125130B2 (en) 2018-11-13
PT3137460T (pt) 2019-12-30
EA201650003A1 (ru) 2017-03-31
PL3137460T3 (pl) 2020-04-30
ES2759434T3 (es) 2020-05-11
SI3137460T1 (sl) 2019-12-31
AU2015254943B2 (en) 2019-04-04
RS59617B1 (sr) 2020-01-31
JP2019214597A (ja) 2019-12-19
CU20160157A7 (es) 2017-05-10
AU2015254943A1 (en) 2016-10-27
WO2015166373A1 (en) 2015-11-05
GT201600232A (es) 2019-10-10
HK1232212A1 (zh) 2018-01-05
CU24420B1 (es) 2019-06-04
NI201600163A (es) 2016-11-25
AP2016009530A0 (en) 2016-10-31
MX2016014143A (es) 2017-02-15
GEP20186879B (en) 2018-07-10
MA49708A (fr) 2020-06-03
SG11201608634RA (en) 2016-11-29
EP3556757A1 (en) 2019-10-23
HUE046518T2 (hu) 2020-03-30
TN2016000459A1 (en) 2018-04-04
JP6574203B2 (ja) 2019-09-11
CA2947130C (en) 2018-10-02
US20170050958A1 (en) 2017-02-23
IL248629B (en) 2019-07-31
PH12016501997B1 (en) 2017-01-09
US10676471B2 (en) 2020-06-09
US20180148441A1 (en) 2018-05-31
SV2016005310A (es) 2017-08-29
UA117861C2 (uk) 2018-10-10
EA033919B1 (ru) 2019-12-10
CA2947130A1 (en) 2015-11-05
EP3137460A1 (en) 2017-03-08
US20190270737A1 (en) 2019-09-05
EP3137460B1 (en) 2019-10-23
US20190040055A1 (en) 2019-02-07
NZ725496A (en) 2019-11-29
PH12016501997A1 (en) 2017-01-09
CY1122439T1 (el) 2020-11-25
DK3137460T3 (da) 2019-12-16
DOP2016000293A (es) 2016-12-30
CN106232598A (zh) 2016-12-14
LT3137460T (lt) 2019-12-10
MA39926B1 (fr) 2019-12-31
CR20160497A (es) 2016-12-20
ECSP16083017A (es) 2017-03-31
IL248629A0 (en) 2017-01-31
PE20161436A1 (es) 2017-01-08
CL2016002532A1 (es) 2017-04-21
CN106232598B (zh) 2020-03-13
BR112016024513A2 (pt) 2017-08-15
KR20160149256A (ko) 2016-12-27
HRP20192056T1 (hr) 2020-02-21
JP2017514818A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
TN2015000281A1 (fr) Lactames condenses aryliques et heteroaryliques
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
IN2015DN01156A (ro)
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12018500061A1 (en) Oxysterols and methods of use thereof
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
IN2014MN02598A (ro)
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
PH12016501462A1 (en) Neprilysin inhibitors
TW201613864A (en) Novel compounds
MD20170011A2 (ro) Compuşi imidazopiridazinici
PH12018500378A1 (en) Novel annelated phenoxyacetamides
PH12016501997A1 (en) Cycloalkyl-linked diheterocycle derivatives
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)